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ABSTRACT
Anti-inflammatory properties of pentoxifylline (PTX) have re-
cently been described. Spontaneously hypertensive stroke-
prone rats (SHRSP) constitute an animal model that develops
an inflammatory condition that precedes the appearance of
brain abnormalities. The aim of the present investigation was to
assess: 1) the efficacy of PTX treatment in protecting the neural
system in SHRSP, and 2) how its anti-inflammatory properties
might be involved in this effect. Male SHRSP fed with a per-
missive diet received no drug or PTX (100 or 200 mg/kg/day).
Brain abnormalities detected by magnetic resonance imaging
developed spontaneously in control rats after 42  3 days,
whereas in rats treated with 100 mg/kg/day PTX, abnormalities
developed in only 80% of the animals and only after 70 to 80
days. Treatment with a higher dose of PTX (200 mg/kg/day)
completely protected the brain from abnormal development.
The drug treatment prevented the accumulation of macro-
phages or CD4 positive cells, the activation of glia in brain
tissues, and the appearance of inflammatory proteins and thio-
barbituric acid-reactive substances in body fluids. PTX treat-
ment did induce a greater increase of serum tumor necrosis
factor- (TNF-), but not of interleukin (IL)-1 and IL-6 induced
by in vivo administration of lipopolysaccharide (LPS), which
suggests a protective role for TNF-. PTX also exerted protec-
tive effects when it was administered after the first occurrence
of proteinuria (40 mg/day). These data indicate that PTX
treatment dose-dependently prevents the occurrence of spon-
taneous brain damage by reducing inflammatory events. We
also hypothesize that the increase of TNF- by PTX treatment
represents a protective mechanism in SHRSP.
Pentoxifylline (PTX), a methylxanthine derivative and
nonspecific type 4 phosphodiesterase inhibitor, is a drug
widely used in the management of peripheral arterial disease
and, in particular, for intermittent claudication (Labs et al.,
1997; Creager, 2001). The mechanism underlying its benefi-
cial effects appears to be related to the improvement of cel-
lular functions and modifications in the plasma that improve
microcirculatory perfusion in both peripheral and cerebral
vascular beds (Seiffge, 1997; Windmeier and Gressner, 1997).
In recent years, in vitro and in vivo experiments indicated
an additional therapeutic potential for PTX as an anti-in-
flammatory and immunomodulator agent (Teixeira et al.,
1997; Laurat et al., 2001; Haddad et al., 2002). This newly
described pharmacological effect can be ascribed to an inhi-
bition of the functional responses of circulating mononuclear
phagocytes, neutrophils, and T lymphocytes and the de-
creased synthesis of several proinflammatory cytokines
(Dong et al., 1997; Neuner et al., 1997; Marcinkiewicz et al.,
2000; Bahra et al., 2001; Laurat et al., 2001; Samardzic et al.,
2001). Studies of the anti-inflammatory effects of PTX in vivo
have focused attention on tissue injury after ischemia. Thus,
in vivo PTX treatment reduced ischemia-reperfusion injury
in the lung (Thabut et al., 2001), intestine (Sener et al.,
2001), liver (Iwamoto et al., 2002), kidney (Kim et al., 2001),
spinal cord (Savas et al., 2002), and brain of different animal
species including rats, mice, and dogs (Toung et al., 1994;
Sirin et al., 1998; Eun et al., 2000). Inflammatory processes
accompany tissue injury regardless of the organ system in-
volved, and chronic inflammation may predispose to isch-
emia in peripheral organs and to brain damage (Lindsberg
and Grau, 2003).
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We have previously reported (Sironi et al., 2001; Guerrini
et al., 2002) that spontaneously hypertensive stroke-prone
rats (SHRSP) subjected to salt loading develop an inflamma-
tory condition characterized by the accumulation of acute-
phase proteins in plasma and urine, and this event precedes
and predicts the appearance of brain abnormalities. This
seems to be a suitable experimental model to explore if the
effect of PTX on tissue damage depends on anti-inflamma-
tory properties. This study was designed to: 1) evaluate the
neuroprotective effect of PTX in salt-loaded SHRSP, and 2) to
understand whether its anti-inflammatory properties are in-
volved. We used the salt-loaded SHRSP, a spontaneous
model of cerebral damage, and measured the onset and de-
velopment of brain damage and increase in survival time
after PTX treatment in either prophylactic or rescue mode.
We found that both regimens delay brain damage and atten-
uate the associated inflammatory responses.
Materials and Methods
Animal Model of Brain Damage. Male SHRSP (8–10 weeks
old), purchased from Charles River Italica (Calco, Como, Italy), were
fed a permissive diet containing 18.7% protein, 0.63% potassium,
0.37% sodium (Laboratorio Dr. Piccioni, Milano, Italy), and 1% NaCl
in drinking water (salt-loaded) ad libitum. Their food and liquid
intakes were measured weekly, as was proteinuria. T2-weighted
MRI assessments were repeated every other day in rats after 24-h
proteinuria exceeded 40 mg/day and daily after a brain abnormality
had been detected (Sironi et al., 2001). Three days after brain dam-
age was detected, the rats were anesthetized with chloral hydrate
(400 mg/kg i.p.), and the brain was removed for immunohistochem-
ical analysis. At the same time, PTX-treated rats with no sign of
brain abnormalities were also sacrificed. Procedures involving ani-
mals and their care were in accordance with the Guide for the Care
and Use of Laboratory Animals.
Drug Treatment. In each experiment, animals were matched for
age and weight and randomly divided into the different treatment
groups. Pentoxifylline [PTX; 3,7 dimethyl-1-(5-oxohexyl) xanthine],
obtained from Sigma-Aldrich (St. Louis, MO), was dissolved daily in
a small amount of drinking water to achieve doses of 100 (n  12) or
200 mg/kg/day (n 12). Each rat was kept in a separate cage, and an
operator ensured that each animal drank the entire drug solution
daily, after which the animal had free access to 1% NaCl. Control
rats (n  12) received the vehicle in the same way as PTX.
Drug treatments were started simultaneously with the permissive
diet in the prophylactic experiment and soon after proteinuria ex-
ceeded 40 mg/day in the rescue therapy. Rats were weighed weekly,
and their arterial blood pressure was measured, then housed indi-
vidually in metabolic cages for 24 h, and urine was collected for
measurement of proteinuria and for proteomic studies.
MRI Evaluations of Brain Damage. The rats were anesthe-
tized with 2% isofluorane in 70% N2/30% O2, fixed to an animal
holder by means of a rod beneath the teeth, and placed inside the
magnet (4.7T, vertical 15-cm bore) of a Bruker spectrometer (AMX3
with micro-imaging accessory; Bruker Biospin, Karlsruhe, DE). A
6.4-cm diameter birdcage coil was used for the imaging. A T2 mul-
tislice image was obtained after a 3-orthogonal plane gradient echo
scout. Sixteen contiguous 1-mm thick slices were analyzed caudally
to the olfactory bulb using a field of view of 4  4 cm2. A turbo spin
echo sequence was used with 16 echoes per excitation, 10 ms of
interecho time, 85 ms of equivalent echo time, and 4 s of repetition
time. The images were 128  128 points (zero filled to 256  256),
and eight images were averaged in 830. The occurrence of lesions
was identified as the presence of areas of high signal intensity on
T2-weighted MRI.
Immunohistochemistry of Brain Tissue. For histological ex-
amination, the brains were fixed in Carnoy reagent (Merck, Darm-
stadt, Germany), embedded in Paraplast (Sigma-Aldrich), and coro-
nal sections (5 m) were stained with hematoxylin/eosin and
examined by light microscopy. For immunohistochemical studies,
paraffin-embedded brain coronal sections were dewaxed in xylene
and dehydrated. Endogenous peroxidase was blocked by adding 1%
H2O2 in 50% methanol. Nonspecific binding sites were saturated
with goat serum. The sections were incubated overnight at 4°C with
the primary antibodies, then with biotinylated secondary antibodies,
and streptavidine peroxidase (LSAB2 kit; DAKO, Glostrup, Den-
mark). Horseradish peroxidase was detected with H2O2 and diami-
nobenzidine (Sigma-Aldrich). The primary antibodies used were:
anti-CD4 which react with T helper cells (1:10; Cymbus Biotechnol-
ogies, Chandlers Ford, Hants, UK), anti-ED1 which react with my-
eloid cells (1:20; Serotec, Oxford, UK), and anti-ED2 which react
with resident macrophages (1:20; Serotec). Microglia were specifi-
cally visualized by lectin histochemistry using peroxidase-labeled
isolectin B4 from Griffonia simplicifolia seeds (Sigma-Aldrich).
Myeloperoxidase (MPO) Tissue Activity. MPO activity was
measured by a modification of the Hillegass technique (Hillegass et
al., 1990). Briefly, 0.1 g of rat brain tissue was homogenized in 4 ml
of 50 mM potassium phosphate buffer, pH 6.0 and centrifuged at
16,000 rpm for 30 min at 4°C. The pellet was resuspended in the
same buffer with 0.5% hexadecyltrimethylammonium bromide. The
samples were alternately frozen and thawed three times and soni-
cated between cycles before another centrifugation (16,000 rpm at
4°C). For the measurement, 0.1 ml of supernatant was mixed with
0.1 ml of tetramethylbenzidine, 16 mM in dimethylsulfoxide, and 0.8
ml of H2O2 0.3 mM. Absorbance was measured at 655 nm for 5 min.
The MPO activity values were expressed as percentage of change in
optical density per minute per gram over tissues from that in non-
salt-loaded rats (100%).
Determination of Urinary Thiobarbituric Acid Reacting
Substances (TBARS). TBARS were measured by the method of
Valenzuela (1991). Briefly, 500 l of urine was combined with 500 l
of a 0.67% thiobarbituric acid (TBA) aqueous solution and 500 l of
20% trichloroacetic acid solution. The samples were vortexed and
incubated at 100°C for 1 h, and the absorbance at 532 nm was
measured spectrophotometrically. The quantity of TBARS is propor-
tional to the amount of malondialdehyde (MDA), a lipid peroxidation
product generated by the oxidation of membrane lipids by reactive
oxygen species. The concentration of MDA was calculated by the
absorbance coefficient of the MDA-TBA complex (absorbance coeffi-
cient   1.56  105 cm-1 M-1) and expressed as percentage of
increase over that in nonsalt-loaded rat urine.
Lipopolysaccharide Induction of Serum TNF-, IL-1, and
IL-6. SHRSPs subjected to the permissive diet were not treated (n 
8) or treated with PTX (200 mg/kg/day; n  8). Three days after
detection of brain abnormalities in control rats, all the animals were
injected with LPS (dissolved in sterile pyrogen-free saline at 5 mg/
kg) to trigger the formation of inflammatory cytokines. Three hours
later, blood samples were collected, serum was prepared by centrif-
ugation at 1200g for 10 min at 4°C, and stored at 80°C until assay.
TNF-, IL-1, and IL-6 levels were determined using an enzyme-
linked immunosorbent assay kit (NIBSC, Hertfordshire, UK) follow-
ing the manufacturer’s instructions.
Proteomic Studies. Urine proteins were concentrated by trichlo-
roacetic acid-acetone precipitation. One-dimensional electrophoresis
was run on urine proteins in the presence of SDS, without sample
reduction, in a discontinuous buffer system on a 4 to 20% polyacryl-
amide gradient. The sample load was 3.75 g per lane. Proteins were
stained with 0.3% w/v Coomassie Blue, and the protein patterns
were digitalized with a scanner.
Statistical Analysis. Data are expressed as mean  S.D. Differ-
ences between groups were computed by analysis of variance for
repeated measurements, followed by Bonferroni’s post hoc test. p 	
0.05 was taken as statistically significant.
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Results
Effects of Pentoxifylline on Physiological Parame-
ters. Body weight increased similarly in the three groups of
salt-loaded SHRSPs up to the sixth week of treatment (Table
1). After that, body weight decreased in control rats only. In
PTX-treated animals, the growth curves constantly increased
over the entire experimental period (not shown). The severe
hypertension that developed in salt-loaded SHRSPs was not
influenced by either dose of PTX used (Table 1).
Effects of Pentoxifylline on Proteinuria and Inflam-
matory Proteins in Urine. In control rats, proteinuria
progressively increased and rose sharply after 4 weeks of salt
loading, reaching a maximum of 166  31.7 mg/day on the
42nd day of treatment. At either dose of PTX, proteinuria
was lower than in the untreated animals. The lower dose
(n 12) resulted in a delayed rise in proteinuria (not shown),
whereas the higher dose (n 12) virtually prevented the loss
of protein (Fig. 1A). The mixture of proteins excreted by
control SHRSP and by those given 200 mg/kg/day of PTX,
was identified by running the urine on one-dimensional gels
(example in Fig. 1B). The appearance of high molecular
weight proteins, markers of an inflammatory response in
control animals, were dramatically delayed in the drug-
treated rats.
Effects of Pentoxifylline on the Appearance of Brain
Damage. All control rats (n  12) developed brain abnor-
malities after 42  3 days of permissive diet, whereas in the
group treated with PTX (100 mg/kg/day, n  12), the abnor-
malities developed in 80% of the animals after 70 to 80 days.
Treatment with the higher dose of PTX (n  12) completely
protected the brain (animals free from MRI-detectable le-
sions after 4 months) (Fig. 2).
Effects of Pentoxifylline on the Appearance of In-
flammatory Cells in the Brain. In control rats, inflamma-
tory cells were found in the damaged brain hemisphere 3
days after MRI first detected the damage. ED1- and ED2-
positive macrophages, CD4 T-lymphocytes, and activated
microglia (isolectin B4 positive) accumulated significantly
(Fig. 3). ED2-positive cells localized preferentially around the
vessels, whereas ED1-positive cells, CD4 T lymphocytes,
and activated microglia, were spread over the whole damage
tissue. Conversely, in PTX-treated animals sacrificed at the
same time as the controls, no inflammatory, immunocompe-
tent, or activated cells could be detected (Fig. 3). In brain
homogenates of control rats, we documented increased MPO
activity (188  27% versus nonsalt-loaded SHRSP), an index
of accumulation of polymorphonuclear neutrophils; this was
not attenuated by PTX treatment (218 16% versus nonsalt-
loaded SHRSP).
Effects of Pentoxifylline on Inflammatory Parame-
ters. Three hours after in vivo administration of LPS, the
induction of TNF- was significantly greater in PTX-treated
rats (n  8) than in controls (n  8) (Fig. 4). However, the
induction of IL-1 and IL-6 was not affected by PTX treat-
ment (Fig. 4). The urinary increase in TBARS found in con-
trol rats after the detection of damage (257  12.2% versus
nonsalt-loaded SHRSP) was almost nullified by PTX treat-
ment (114  24.7% versus nonsalt-loaded SHRSP).
Effects of Pentoxifylline Administered after In-
crease of Proteinuria. To determine whether the PTX re-
versed the increase in proteinuria, SHRSPs subjected to salt
loading and permissive diet (n  10) were treated with drug
(200 mg/kg/day; n  10) after 40 mg protein/day were lost
in the urine. This treatment also protected the animals from
loss in weight, any further increase in proteinuria, and from
the development of MRI-detectable brain lesions (not shown).
Discussion
We have shown here that prophylactic treatment with PTX
delays, in a dose-dependent manner, the onset and develop-
ment of brain damage and increases survival in salt-loaded
SHRSP. These effects are independent of blood pressure and
are linked to a mitigation of the local and systemic inflam-
matory responses always associated with brain damage in
this animal model. Similar results were obtained when PTX
administration was delayed.
We have reported earlier that the gray matter of rat brain
that develops damage after salt loading is markedly spongy
with loss of neurons, accumulation of astrocytes, and depo-
sition of fibrinoid-eosinophilic material (Sironi et al., 2001,
2003; Guerrini et al., 2002). Now, we have shown a local
response close to the brain-damaged area of salt-loaded
SHRSP, with the accumulation of inflammatory as well as
immunocompetent cells. Resident macrophages (ED2) in the
damaged area may be activated by proinflammatory cyto-
kines, which in turn may alter the biochemical and physical
properties of the blood-brain barrier. Circulating macro-
phages (ED1) migrate through the vasculature of the im-
paired blood-brain barrier and surround the damaged tissue,
thus favoring local progression of the ischemic process. CD4
T lymphocytes and neutrophils are also recruited into the
inflammatory brain area. PTX treatment suppressed recruit-
ment within the brain of inflammatory cells, with the excep-
tion of polymorphonuclear neutrophils, and maintained thio-
barbituric acid-reactive substances at their normal level.
Several complementary anti-inflammatory effects of PTX
could be responsible for its neuroprotective effect. One pos-
sible mechanism is the inhibition of cellular functions in-
volved in inflammatory and immune diseases, inhibition of
adhesion and activation of peripheral blood T-lymphocytes,
suppression of T-cell proliferation and differentiation, and
inhibition of polarization and migration of human leukocytes
and neutrophils (Dong et al., 1997; Gonzalez-Amaro et al.,
1998; Laurat et al., 2001; Dominguez-Jime´nez et al., 2002). A
second neuroprotective mechanism of PTX probably includes
the inhibition of the generation of oxygen radicals. Oxidative
stress may damage different tissues such as the brain and
the kidney in SHRSP (Tanito et al., 2004). It has been docu-
mented that PTX protects against lipid peroxidation in in
vitro and in vivo models of ischemia (Bhat and Madyastha,
2001).
Lipopolysaccharide injection induced higher levels of
TABLE 1
Body weight and blood pressure for salt-loaded SHRSPs treated with





Not treated 265  9 257  29
PTX 100 mg/kg/day 273  6 235  10
PTX 200 mg/kg/day 275  3 244  18
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TNF- (but not of IL-1 or IL-6) in PTX-treated rats than in
controls. TNF- has been implicated in brain damage, but
also in neuroprotective effects in stroke (Hallenbeck, 2002),
and several recent studies postulate an important role for
TNF- in ischemic preconditioning (Ginis et al., 2002). Isch-
emic tolerance associated with increased plasma levels of
TNF- has recently been reported in human stroke (Castillo
et al., 2003). On this basis, we hypothesize that the propen-
sity of PTX-treated rats to produce TNF- may represent a
protective mechanism.
The appearance of brain damage in salt-loaded SHRSP is
always preceded by proteinuria and the accumulation of sev-
eral inflammatory markers in plasma and urine (Sironi et al.,
2001). Most of the acute phase proteins (transferrin, he-
mopexin, albumin, and thiostatin) found in serum are also
detected in urine, and their levels increase over time until
stroke occurs. The total amount and the composition of pro-
teins in the urine changes during the 2 weeks preceding an
ischemic event (Sironi et al., 2001). We therefore tried treat-
ing the salt-loaded SHRSPs with PTX immediately after the
appearance of inflammatory proteins in the urine. Even this
delayed administration protected the animals from the de-
velopment of brain damage as well as from the linear in-
crease of urinary protein, which suggests that PTX may “cure
or reverse” the kidney abnormalities reported in this animal
model (Abumiya et al., 1996). Indeed, a nephroprotective
effect of PTX in experimentally induced renal failure (Kim et
al., 2001) and an antiproteinuric effect in patients with ne-
phropathy (Ducloux et al., 2001) has been reported.
Methylxanthine derivatives are of potential interest in the
treatment of vascular diseases, in general, and of stroke, in
particular, because of their vasodilating properties (Kruuse
et al., 2000). PTX has been reported to increase peripheral
blood flow and walking distance in those with arterial dis-
ease (Creager, 2001). Results on the effect of PTX on cerebral
blood flow are not consistent; the discrepancies could be
ascribed either to the different dosages or routes of adminis-
tration (Kruuse et al., 2000). Preclinical studies suggest that
Fig. 1. Effects of pentoxifylline on urinary proteins in SHRSP. A, daily proteinuria as a function of the duration of salt loading, for control SHRSPs
Œ or 200 mg/kg/day pentoxifylline f (, p 	 0.01). B, representative one-dimensional electrophoresis of urinary proteins, collected weekly, from a
control SHRSP (left) or one receiving 200 mg/kg/day pentoxifylline (right). Samples of 3.75 g from a 24-h collection from a metabolic cage were loaded
per lane. Gels shown are representative of results obtained in four rats. MUP, major urinary protein; SA, albumin; Tf, transferrin.
Fig. 2. Effects of pentoxifylline on the ap-
pearance of brain damage in SHRSP. Event-
free survival as a function of the duration of
salt loading for control SHRSPs (n  12) Œ,
SHRSP treated with 100 mg/kg/day pentoxi-
fylline (n  12) F, and with 200 mg/kg/day
(n  12) f.
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Fig. 3. Immunohistochemical analysis of inflammatory cells within the brain of SHRSP. Representative immunohistochemical staining of ED1, ED2,
isolectin-B4, and CD4 of brain slices obtained from control SHRSP (A–D) or treated with pentoxifylline (200 mg/kg/day; E–H) and sacrificed 3 days
after the MRI detection of brain damage in the control group. Result is representative of data obtained in five independent experiments with brain
from different rats (magnification 20; 40 for C and G).
Fig. 4. Effects of pentoxifylline of serum levels of cytokines in SHRSP. Effects on control (n  8) and pentoxifylline-treated rats (200 mg/kg/day; n 
8) on LPS-induced serum levels of TNF-, IL-1, and IL-6 in salt-loaded SHRSP. Three days after detection of brain abnormalities in vehicle-treated
rats, the animals of both experimental groups were injected with LPS. Blood samples were collected 3 h after LPS injection. , p 	 0.05
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pentoxifylline and propentofylline reduce neural damage fol-
lowing ischemia (Labs et al., 1997; Teixeira et al., 1997).
Similarly, uncontrolled open trials have suggested that PTX
may improve stroke outcome in humans (Bath et al., 2000). A
recent meta-analysis that included five trials with methylx-
anthines, administered either intravenously or orally, found
insufficient evidence to assess the effectiveness and safety of
methylxanthines after acute ischemic stroke (Bath et al.,
2000). However, a collaborative group is being formed to
further assess the effects of methylxanthine derivatives in
stroke patients in view of their multiple pharmacological
properties as anti-inflammatories, inhibitors of free radical
production, neuroprotectors, vasodilators, and antiplatelet
agents (Bath et al., 2000).
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